drugset
drugset / Trial / NCT03786926

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

NCT03786926 ↗

Phase 1 Terminated 53 enrolled Hutchmed
NaSingle-groupOpen-labelTreatment

Summary

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

Timeline

Start
2019-08-26
Primary completion
2024-06-26
Completion
2024-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AMDIZALISIB Small molecule — Oral

Indications

lymphoma